Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03573596
Title Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment (DASTOP2)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors VU University Medical Center
Indications

chronic myeloid leukemia

Therapies

Dasatinib

Age Groups: adult
Covered Countries FRA | DEU


No variant requirements are available.